Miltefosine: new preparation. Solution for cutaneous application.
In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated.  Complete remission was achieved in only 6% of cases in non comparative trials, and the median duration before progression resumed was 6 months.  Miltefosine can have many local adverse effects.
D000279:Administration, Cutaneous; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D003401:Creatine / Q000097:blood; D004798:Enzymes / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010349:Patient Compliance; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D012871:Skin Diseases; D012878:Skin Neoplasms / Q000556:secondary / Q000628:therapy*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D004798:Enzymes; D010767:Phosphorylcholine; D003401:Creatine